Related Experiment Video

Updated: Apr 6, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

6.0K

Angiotensin receptor blockers are not associated with reduced inflammatory markers in the general population

Pedro Marques-Vidal1, Peter Vollenweider, Gérard Waeber

  • 1Department of Internal Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland.

Journal of Hypertension
|August 4, 2015
PubMed

Insights

Angiotensin receptor blockers (ARBs) did not show a reduction in inflammatory markers like CRP or interleukins in a general population study. These findings suggest ARBs may not be effective for reducing inflammation in non-clinical settings.

Area of Science:

  • Cardiovascular Research
  • Inflammation Biology
  • Pharmacology

Background:

  • Randomized controlled trials suggest Angiotensin Receptor Blockers (ARBs) may possess anti-inflammatory properties.
  • The association between ARBs and inflammatory markers in a general population remains underexplored.

Purpose of the Study:

  • To investigate the association between Angiotensin Receptor Blockers (ARBs) and key inflammatory markers in a general population.
  • To determine if ARBs reduce levels of C-reactive protein (CRP), interleukin-1β, interleukin-6, and tumor necrosis factor alpha (TNF-α).

Main Methods:

  • Population-based prospective study in Lausanne, Switzerland, with baseline (2003-2006) and follow-up (2009-2012) data.
  • Assessed inflammatory markers (CRP, IL-1β, IL-6, TNF-α) in 933 (baseline) and 1120 (follow-up) participants, with 424 and 572 on ARBs, respectively.
  • Utilized multivariate adjustment and compared ARB users with non-users and users of other antihypertensives.

Main Results:

  • No significant differences in baseline or follow-up inflammatory marker levels were observed between participants on ARBs and those not on ARBs.
  • Multivariate analysis showed no association between ARB use and higher quartiles of CRP, IL-1β, IL-6, or TNF-α at baseline or follow-up.
  • Comparison of long-term ARB users with users of other antihypertensives also revealed no significant effect on inflammatory markers.

Conclusions:

  • Angiotensin Receptor Blockers (ARBs) are not associated with reduced levels of key inflammatory markers in the general population.
  • The anti-inflammatory effects suggested by some trials may not translate to real-world, non-clinical settings.
  • Further research may be needed to clarify the role of ARBs in inflammation.
Abstract

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
770
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
564